114 related articles for article (PubMed ID: 36596519)
1. BET Inhibitors Induce p53-Independent Growth Arrest in HCT116 Cells via Epigenetic Control of the E2F1/c-MYC Axis.
Jeon D; Kim N; Um SJ
Biol Pharm Bull; 2023; 46(1):12-18. PubMed ID: 36596519
[TBL] [Abstract][Full Text] [Related]
2. Adenovirus E1A oncoprotein liberates c-Myc activity to promote cell proliferation through abating Bin1 expression via an Rb/E2F1-dependent mechanism.
Kinney EL; Tanida S; Rodrigue AA; Johnson JK; Tompkins VS; Sakamuro D
J Cell Physiol; 2008 Sep; 216(3):621-31. PubMed ID: 18348166
[TBL] [Abstract][Full Text] [Related]
3. Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells.
Tögel L; Nightingale R; Chueh AC; Jayachandran A; Tran H; Phesse T; Wu R; Sieber OM; Arango D; Dhillon AS; Dawson MA; Diez-Dacal B; Gahman TC; Filippakopoulos P; Shiau AK; Mariadason JM
Mol Cancer Ther; 2016 Jun; 15(6):1217-26. PubMed ID: 26983878
[TBL] [Abstract][Full Text] [Related]
4. TIGAR induces p53-mediated cell-cycle arrest by regulation of RB-E2F1 complex.
Madan E; Gogna R; Kuppusamy P; Bhatt M; Pati U; Mahdi AA
Br J Cancer; 2012 Jul; 107(3):516-26. PubMed ID: 22782351
[TBL] [Abstract][Full Text] [Related]
5. p53-independent induction of G1 arrest and p21WAF1/CIP1 expression by ascofuranone, an isoprenoid antibiotic, through downregulation of c-Myc.
Jeong JH; Kang SS; Park KK; Chang HW; Magae J; Chang YC
Mol Cancer Ther; 2010 Jul; 9(7):2102-13. PubMed ID: 20587660
[TBL] [Abstract][Full Text] [Related]
6. Myc and E2F1 induce p53 through p14ARF-independent mechanisms in human fibroblasts.
Lindström MS; Wiman KG
Oncogene; 2003 Aug; 22(32):4993-5005. PubMed ID: 12902982
[TBL] [Abstract][Full Text] [Related]
7. Co-inhibition of BET proteins and NF-κB as a potential therapy for colorectal cancer through synergistic inhibiting MYC and FOXM1 expressions.
Wu T; Wang G; Chen W; Zhu Z; Liu Y; Huang Z; Huang Y; Du P; Yang Y; Liu CY; Cui L
Cell Death Dis; 2018 Feb; 9(3):315. PubMed ID: 29472532
[TBL] [Abstract][Full Text] [Related]
8. Ei24, a novel E2F target gene, affects p53-independent cell death upon ultraviolet C irradiation.
Sung YH; Jin Y; Kang Y; Devkota S; Lee J; Roh JI; Lee HW
J Biol Chem; 2013 Oct; 288(43):31261-7. PubMed ID: 24014029
[TBL] [Abstract][Full Text] [Related]
9. A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma.
Kling MJ; Kesherwani V; Mishra NK; Alexander G; McIntyre EM; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
J Exp Clin Cancer Res; 2022 Nov; 41(1):321. PubMed ID: 36357906
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1.
Shahbazi J; Scarlett CJ; Norris MD; Liu B; Haber M; Tee AE; Carrier A; Biankin AV; London WB; Marshall GM; Lock RB; Liu T
Oncotarget; 2014 Jun; 5(12):4257-68. PubMed ID: 24952595
[TBL] [Abstract][Full Text] [Related]
11. The BET Bromodomain Inhibitor JQ1 Suppresses Chondrosarcoma Cell Growth via Regulation of YAP/p21/c-Myc Signaling.
Zhang HT; Gui T; Sang Y; Yang J; Li YH; Liang GH; Li T; He QY; Zha ZG
J Cell Biochem; 2017 Aug; 118(8):2182-2192. PubMed ID: 28059436
[TBL] [Abstract][Full Text] [Related]
12. Genetic modifiers of the BRD4-NUT dependency of NUT midline carcinoma uncovers a synergism between BETis and CDK4/6is.
Liao S; Maertens O; Cichowski K; Elledge SJ
Genes Dev; 2018 Sep; 32(17-18):1188-1200. PubMed ID: 30135075
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of BET bromodomain targets genetically diverse glioblastoma.
Cheng Z; Gong Y; Ma Y; Lu K; Lu X; Pierce LA; Thompson RC; Muller S; Knapp S; Wang J
Clin Cancer Res; 2013 Apr; 19(7):1748-59. PubMed ID: 23403638
[TBL] [Abstract][Full Text] [Related]
14. Redeployment of Myc and E2f1-3 drives Rb-deficient cell cycles.
Liu H; Tang X; Srivastava A; Pécot T; Daniel P; Hemmelgarn B; Reyes S; Fackler N; Bajwa A; Kladney R; Koivisto C; Chen Z; Wang Q; Huang K; Machiraju R; Sáenz-Robles MT; Cantalupo P; Pipas JM; Leone G
Nat Cell Biol; 2015 Aug; 17(8):1036-48. PubMed ID: 26192440
[TBL] [Abstract][Full Text] [Related]
15. Epithelial cell-derived periostin functions as a tumor suppressor in gastric cancer through stabilizing p53 and E-cadherin proteins via the Rb/E2F1/p14ARF/Mdm2 signaling pathway.
Lv H; Liu R; Fu J; Yang Q; Shi J; Chen P; Ji M; Shi B; Hou P
Cell Cycle; 2014; 13(18):2962-74. PubMed ID: 25486483
[TBL] [Abstract][Full Text] [Related]
16. p53-Dependent transcriptional repression of c-myc is required for G1 cell cycle arrest.
Ho JS; Ma W; Mao DY; Benchimol S
Mol Cell Biol; 2005 Sep; 25(17):7423-31. PubMed ID: 16107691
[TBL] [Abstract][Full Text] [Related]
17. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
[TBL] [Abstract][Full Text] [Related]
18. Bromodomain and extra-terminal motif (BET) inhibition is synthetic lethal with loss of SMAD4 in colorectal cancer cells via restoring the loss of MYC repression.
Shi C; Yang EJ; Liu Y; Mou PK; Ren G; Shim JS
Oncogene; 2021 Feb; 40(5):937-950. PubMed ID: 33293694
[TBL] [Abstract][Full Text] [Related]
19. p53 Suppresses E2F1-dependent PLK1 expression upon DNA damage by forming p53-E2F1-DNA complex.
Zhou Z; Cao JX; Li SY; An GS; Ni JH; Jia HT
Exp Cell Res; 2013 Dec; 319(20):3104-15. PubMed ID: 24076372
[TBL] [Abstract][Full Text] [Related]
20. Antimyeloma activity of bromodomain inhibitors on the human myeloma cell line U266 by downregulation of MYCL.
Suzuki K; Yamamoto K; Arakawa Y; Yamada H; Aiba K; Kitagawa M
Anticancer Drugs; 2016 Sep; 27(8):756-65. PubMed ID: 27276402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
